La stratégie thérapeutique est décr

La stratégie thérapeutique est décrite en figure 2.
Avant tout réajustement thérapeutique, il est nécessaire :
•
d’envisager la responsabilité éventuelle :
o
de la qualité de la prescription médicale (précision des doses et horaires de prise) et de son respect par la PcP (importance de l’explication médicale et de l’évaluation de la compréhension des PcP et accompagnants principaux),
•
de médicaments associés susceptibles d’aggraver les complications motrices et non motrices :
o
pour les périodes off (neuroleptiques cachés ou atypiques, sauf la clozapine),
o
pour les dyskinésies : par médication ou automédication excessive en L-dopa, IMAO B, agonistes dopaminergiques, et inhibiteurs de la catéchol-O-méthyl transférase (ICOMT) ;
•
de faire un état journalier minutieux de l’évolution motrice et d’évaluer en particulier la réponse à la première prise matinale de L-Dopa ;

결과 (영어) 1:

The therapeutic strategy is described in figure 2.Before any therapeutic readjustment, it is necessary:•consider the potential liability:othe quality of the medical prescription (accuracy of dose) and socket schedules and its respect by the CFP (importance of medical explanation and evaluation of the main understanding of the CFP and accompanying persons),•likely to exacerbate motor complications and motor related drugs:ofor the off periods (hidden or atypical neuroleptics except clozapine),.ofor dyskinesias: by medication or self-medication excessive L-dopa, MAOI B, dopamine agonists, and inhibitors of catechol-O-methyl transferase (ICOMT);•make a careful daily State driving evolution and assess in particular the response to the first taking morning l-dopa;

결과 (영어) 2:

The therapeutic strategy is described in Figure 2.
Before any therapeutic readjustment, it is necessary:
​​•
to consider the potential liability:
o
the quality of the medical prescription (accuracy of dose and dosing schedule) and compliance by PcP (importance of medical explanation and evaluation of understanding PcP and main carers)
•
medicines that might aggravate associated motor and non-motor complications:
o
for off periods (hidden or atypical neuroleptics, except clozapine),
o
for dyskinesias: excessive self-medication by medication or L-dopa, MAO B, dopamine agonists and inhibitors of catechol-O-methyl transferase (ICOMT);
•
make a detailed daily state of motor development and assessing in particular the response to the first morning dose of L-Dopa;

결과 (영어) 3:

The therapeutic strategy is described in figure 2.
before any therapeutic readjustment, it is necessary :
"
to consider the potential liability :
o
of the quality of the medical prescription (accuracy of the doses and schedules of socket) and of its compliance with the CFP (importance of the medical explanation and of the assessment of the understanding of PCP and accompanying persons main) ,
"